5 Fatemeh Heidary and Reza Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID19 complementary regimen, The Journal of Antibiotics (June 12, 2020), https://www.nature.com/articles/s41429-020-0336-z
6 “Lab experiments show antiparasitic drug, Ivermectin, eliminates SARS-CoV-2 in cells in 48 hours.” Monash Biomedicine Discovery Institute (April 3, 2020), https://www.monash.edu/discovery-institute/news-and-events/news/2020-articles/Lab-experiments-show-anti-parasitic-drug,-Ivermectin,-eliminates-SARS-CoV-2-in-cells-in-48-hours
7 Ibid.
8 Juan Chamie-Quintero et al., “Ivermectin for COVID in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted,” OSF Preprints (March 8, 2021), https://osf.io/9egh4/
9 Hector Carvallo, et al., “Study of the Efficacy and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID19 in Health Personnel,” Journal of Biomedical Research and Clinical Investigation V. 2 I 1 at 1007 (Nov. 17, 2020), https://www.medicalpressopenaccess.com/single_article.php?refid=82
10 Alam et al., “Ivermectin as Pre-exposure Prophylaxis for COVID19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka—An Observational Study,” European Journal of Medical & Health Sciences, Vol. 2 No. 6 (Published December 15, 2020).
11 AD Santin, et al., “Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge,” 43:100924 New Microbes New Infect (Aug. 3, 2021) doi: 10.1016/j.nmni.2021.100924, https://pubmed.ncbi.nlm.nih.gov/34466270/
12 Statement to U.S. Committee on Homeland Security and Governmental Affairs: “Early Outpatient Treatment: An Essential Part of the COVID19 Solution, Part II.” THE ICON STUDY: Dr. Jean-Jacques Rajter Reviews Ivermectin, Hope Pressworks (January 18, 2021), https://hopepressworks.org/f/the-icon-study-dr-jean-jacques-rajter-reviews-ivermectin
13 Alam et al., “Ivermectin as Pre-exposure Prophylaxis for COVID19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka—An Observational Study,” Alam et al., European Journal of Medical & Health Sciences, Vol. 2 No. 6 (Published December 15, 2020), https://www.ejmed.org/index.php/ejmed/article/view/599
14 Peter A. McCullough et al., “Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID19),” Reviews in Cardiovascular Medicine, 2020, Vol. 21 Issue (4): 517-530 https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.04.264
15 Ivermectineforcovid.com, “A Letter to NIH and Dr. Anthony Fauci. Is Anybody Home?,” Ivermectin for COVID (Mar. 4, 2021), https://ivermectinforcovid.com/a-letter-to-nih-and-dr-anthony-fauci-is-anybody-home/
16 C. Bernigaud et al., “Bénéfice de l’ivermectine: de la gale à la COVID19, un exemple de sérendipité,” Annales de Dermatologie et de Vénéréologie (December, 2020), https://www.sciencedirect.com/science/article/abs/pii/S015196382030627X?via%3Dihub
17 C. Bernigaud et al., “Ivermectin benefit: from scabies to COVID19, an example of serendipity,” Annals of Dermatology and Venereology (December, 2020), https://c19ivermectin.com/bernigaud.html
18 Choudhury, Abhigyan et al.,“Exploring the Binding Efficacy of Ivermectin against the Key Proteins of SARS-CoV-2 Pathogenesis: An in Silico Approach,” Future Virology (March 25, 2021), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/
19 Peter A. McCullough et al., “Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID19),” Vol. 6 No. 03 (March, 2021) | Page No.: 219–221
20 “FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID19 Treatment Guidelines Panel to Present Latest Data on Ivermectin,” Press Release, Front Line COVID19 Critical Care Alliance (FLCCC) (January 7, 2021), https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-PressRelease-NIH-C19-Panel-FollowUp-Jan7-2021.pdf
21 Dr. Andrew Hill, “Covid19: WHO-sponsored preliminary review indicates Ivermectin effectiveness,” Dr. Andrew Hill, Swiss Policy Research (December 31, 2020), https://swprs.org/who-preliminary-review-confirms-Ivermectin-effectiveness/
22 Carlos Chaccour, “The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID19: A pilot, double-blind, placebo-controlled, randomized clinical trial,” EClinical Medicine Published by the Lancet, (Jan 19, 2021), https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30464-8/fulltext
23 Pierre Kory, et al., “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID19,” Front Line COVID-10 Critical Care Alliance (Jan 16, 2021), https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID19.pdf
24 “Dr. Pierre Kory, president of the FLCCC Alliance testifies before Senate Committee on Homeland Security and Governmental Affairs looking into early outpatient COVID19 treatment,” Press release, Front Line COVID19 Critical Care Alliance (FLCCC) (December 8, 2020), https://www.newswise.com/coronavirus/dr-pierre-kory-president-of-the-flccc-alliance-testifies-before-senate-committee-on-homeland-security-and-governmental-affairs-looking-into-early-outpatient-covid19-treatment
25 Pierre Kory et al., “Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID19,” Journal of Intensive Care Medicine (December 15, 2020), https://journals.sagepub.com/doi/10.1177/0885066620973585
26 “One Page Summary of the Clinical Trials Evidence for Ivermectin in COVID19,” Front Line COVID19 Critical Care Alliance (FLCCC) (January 11, 2021), https://covid19criticalcare.com/wp-content/uploads/2020/12/One-Page-Summary-of-the-Clinical-Trials-Evidence-for-Ivermectin-inCOVID-19.pdf
27 Testimony by Dr. Pierre Kory to the U.S. Senate Committee on Homeland Security and Governmental Affairs (2020), Front Line COVID19 Critical Care Alliance (FLCCC), https://covid19criticalcare.com/senate-testimony/
28 “FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID19 Treatment Guidelines Panel to Present Latest Data on Ivermectin,” Press Release, Front Line COVID19 Critical Care Alliance (FLCCC) (January 7, 2021), https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-PressRelease-NIH-C19-Panel-FollowUp-Jan7-2021.pdf
29 Donato Paolo Mancini, “Cheap antiparasitic could cut chance of Covid19 deaths by up to 75%,” The Financial Times (January 19, 2021), https://www.ft.com/content/e7cb76fc-da98-4a31-9c1f-926c58349c84
30 “NIH Updates its Position on Ivermectin,” COVEXIT: COVID19 News & Policy Analysis (January 14, 2021), https://covexit.com/nih-updates-its-position-on-ivermectin/